Triplet Regimen of Metronomic Capecitabine Plus Antiangiogenic Drug and PD‐1 Inhibitor as Later‐Line Salvage Treatment for Patients With MSS/pMMR Metastatic Colorectal Cancer: A Retrospective Study

ABSTRACT Later‐line treatment has demonstrated limited survival benefits in patients with metastatic colorectal cancer (mCRC). This retrospective study evaluated the efficacy and safety of a triplet regimen combining metronomic capecitabine, antiangiogenic drugs, and PD‐1 inhibitors in patients with...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Qiong Yang, Yuan‐Yuan Huang, Kai‐Cong Zhang, Qiu‐Sheng Lan, Jie‐Peng Liang, Hui‐Xin Xu, Ya‐Jing Liu, Jing‐Shu Wang, Hui‐Min Liang, He‐Rui Yao, Zhong‐Hua Chu, Hai Hu
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Wiley 2025-07-01
Serie:	MedComm
Soggetti:	immunotherapy metastatic colorectal cancer (mCRC) metronomic chemotherapy microsatellite stable/mismatch repair proficient (MSS/pMMR) targeted therapy
Accesso online:	https://doi.org/10.1002/mco2.70174
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!